AstraZeneca Announced Saturday,Perioperative IMFINZI Plus Neoadjuvant Enfortumab Vedotin Cuts Recurrence Risk 49%, Death Risk 42% Versus Standard Of Care In Muscle-Invasive Bladder Cancer Patients Ineligible For Or Refusing Cisplatin, VOLGA Phase III
Benzinga Newsdesk 1 week ago
News
More than three quarters of patients were still alive two years after treatment with perioperative IMFINZI plus three cycles of EV given before surgeryData demonstrated statistically significant and clinically
More than three quarters of patients were still alive two years after treatment with perioperative IMFINZI plus three cycles of EV given before surgery
Data demonstrated statistically significant and clinically meaningful survival benefit and manageable safety profile